Immuron & Monash University to develop a Clostridium difficile therapeutic
Immuron Limited has entered into a collaboration agreement with Monash University to develop a product or products that will be aimed at both prevention and treatment of Clostridium difficile (C. difficile) infections. The therapeutic will be based on Immuron’s hyper-immune colostrum platform technology, with its proven safety.
C. difficile infections have become a major medical problem especially in hospitals and long-term care facilities because the bacteria produce toxins that cause inflammation of the colon, causing severe diarrhoea and, in serious cases, death. An estimated 28,000 people die each year from these infections in the USA alone.
Monash University has received government funding through an ARC Linkage grant. As is typical with these grants, Immuron and Monash will together own the technology to be generated and Immuron has the exclusive global commercialisation rights.
Other news from the department science
